190 related articles for article (PubMed ID: 25753566)
1. Angiogenic biomarkers in pregnancy: defining maternal and fetal health.
Rasmussen LG; Lykke JA; Staff AC
Acta Obstet Gynecol Scand; 2015 Aug; 94(8):820-32. PubMed ID: 25753566
[TBL] [Abstract][Full Text] [Related]
2. Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study.
Kim MY; Buyon JP; Guerra MM; Rana S; Zhang D; Laskin CA; Petri M; Lockshin MD; Sammaritano LR; Branch DW; Porter TF; Merrill JT; Stephenson MD; Gao Q; Karumanchi SA; Salmon JE
Am J Obstet Gynecol; 2016 Jan; 214(1):108.e1-108.e14. PubMed ID: 26432463
[TBL] [Abstract][Full Text] [Related]
3. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension.
Noori M; Donald AE; Angelakopoulou A; Hingorani AD; Williams DJ
Circulation; 2010 Aug; 122(5):478-87. PubMed ID: 20644016
[TBL] [Abstract][Full Text] [Related]
4. Angiogenic biomarkers for prediction of early preeclampsia onset in high-risk women.
Moore Simas TA; Crawford SL; Bathgate S; Yan J; Robidoux L; Moore M; Maynard SE
J Matern Fetal Neonatal Med; 2014 Jul; 27(10):1038-48. PubMed ID: 24066977
[TBL] [Abstract][Full Text] [Related]
5. Soluble fms-like tyrosine kinase-1 and soluble endoglin in HIV-associated preeclampsia.
Govender N; Naicker T; Rajakumar A; Moodley J
Eur J Obstet Gynecol Reprod Biol; 2013 Sep; 170(1):100-5. PubMed ID: 23806447
[TBL] [Abstract][Full Text] [Related]
6. Gestational angiogenic biomarker patterns in high risk preeclampsia groups.
Maynard SE; Crawford SL; Bathgate S; Yan J; Robidoux L; Moore M; Moore Simas TA
Am J Obstet Gynecol; 2013 Jul; 209(1):53.e1-9. PubMed ID: 23517919
[TBL] [Abstract][Full Text] [Related]
7. Circulating Angiogenic Factors and the Risk of Preeclampsia in Systemic Lupus Erythematosus Pregnancies.
Leaños-Miranda A; Campos-Galicia I; Berumen-Lechuga MG; Molina-Pérez CJ; García-Paleta Y; Isordia-Salas I; Ramírez-Valenzuela KL
J Rheumatol; 2015 Jul; 42(7):1141-9. PubMed ID: 25979720
[TBL] [Abstract][Full Text] [Related]
8. Circulating angiogenic factors and urinary prolactin as predictors of adverse outcomes in women with preeclampsia.
Leaños-Miranda A; Campos-Galicia I; Ramírez-Valenzuela KL; Chinolla-Arellano ZL; Isordia-Salas I
Hypertension; 2013 May; 61(5):1118-25. PubMed ID: 23460287
[TBL] [Abstract][Full Text] [Related]
9. Discordant clinical presentations of preeclampsia and intrauterine fetal growth restriction with similar pro- and anti-angiogenic profiles.
Alahakoon TI; Zhang W; Trudinger BJ; Lee VW
J Matern Fetal Neonatal Med; 2014 Dec; 27(18):1854-9. PubMed ID: 24397483
[TBL] [Abstract][Full Text] [Related]
10. First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia.
Baumann MU; Bersinger NA; Mohaupt MG; Raio L; Gerber S; Surbek DV
Am J Obstet Gynecol; 2008 Sep; 199(3):266.e1-6. PubMed ID: 18771978
[TBL] [Abstract][Full Text] [Related]
11. Maternal, gestational and neonatal characteristics and maternal angiogenic factors in normotensive pregnancies.
Staff AC; Harsem NK; Braekke K; Hyer M; Hoover RN; Troisi R
Eur J Obstet Gynecol Reprod Biol; 2009 Mar; 143(1):29-33. PubMed ID: 19135290
[TBL] [Abstract][Full Text] [Related]
12. Emerging new biomarkers of preeclampsia.
Polsani S; Phipps E; Jim B
Adv Chronic Kidney Dis; 2013 May; 20(3):271-9. PubMed ID: 23928393
[TBL] [Abstract][Full Text] [Related]
13. Added value of angiogenic factors for the prediction of early and late preeclampsia in the first trimester of pregnancy.
Crovetto F; Figueras F; Triunfo S; Crispi F; Rodriguez-Sureda V; Peguero A; Dominguez C; Gratacos E
Fetal Diagn Ther; 2014; 35(4):258-66. PubMed ID: 24714555
[TBL] [Abstract][Full Text] [Related]
14. The relationship between circulating endothelin-1, soluble fms-like tyrosine kinase-1 and soluble endoglin in preeclampsia.
Aggarwal PK; Chandel N; Jain V; Jha V
J Hum Hypertens; 2012 Apr; 26(4):236-41. PubMed ID: 21451568
[TBL] [Abstract][Full Text] [Related]
15. Levels of antiangiogenic factors in preeclamptic pregnancies.
Zhao W; Qiao J; Zhang Q; Zhao Y; Chen Q
Growth Factors; 2010 Aug; 28(4):293-8. PubMed ID: 20214506
[TBL] [Abstract][Full Text] [Related]
16. Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis.
Kleinrouweler CE; Wiegerinck MM; Ris-Stalpers C; Bossuyt PM; van der Post JA; von Dadelszen P; Mol BW; Pajkrt E;
BJOG; 2012 Jun; 119(7):778-87. PubMed ID: 22433027
[TBL] [Abstract][Full Text] [Related]
17. Angiogenic balance in pregnancy and subsequent breast cancer risk and survival: a population study.
Vatten LJ; Romundstad PR; Jenum PA; Eskild A
Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):2074-8. PubMed ID: 19567504
[TBL] [Abstract][Full Text] [Related]
18. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.
Levine RJ; Lam C; Qian C; Yu KF; Maynard SE; Sachs BP; Sibai BM; Epstein FH; Romero R; Thadhani R; Karumanchi SA;
N Engl J Med; 2006 Sep; 355(10):992-1005. PubMed ID: 16957146
[TBL] [Abstract][Full Text] [Related]
19. Circulating concentrations of soluble endoglin (CD105) in fetal and maternal serum and in amniotic fluid in preeclampsia.
Staff AC; Braekke K; Johnsen GM; Karumanchi SA; Harsem NK
Am J Obstet Gynecol; 2007 Aug; 197(2):176.e1-6. PubMed ID: 17689641
[TBL] [Abstract][Full Text] [Related]
20. Angiogenic imbalance and plasma lipid alterations in women with preeclampsia from a developing country.
Reyes LM; García RG; Ruiz SL; Broadhurst D; Aroca G; Davidge ST; López-Jaramillo P
Growth Factors; 2012 Jun; 30(3):158-66. PubMed ID: 22486210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
